💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Imipramine

CHEMBL11 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
280.4 g/mol
LogP
4.8
Phase
4

This tricyclic antidepressant (TCA) works by blocking the reuptake of serotonin and norepinephrine, increasing the availability of these neurotransmitters in the brain. It is used to treat depression, anxiety disorders, and childhood enuresis (bedwetting). Like all TCAs, it has more side effects than newer antidepressants and can be dangerous in overdose.

Молекулярная масса

280,4000 g/mol

LogP

4,80

TPSA

6,50 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Cardiovascular Disease Pain Management Schizophrenia Generalized Anxiety Disorder Gastroesophageal Reflux Disease Major Depressive Disorder Breast Cancer Chronic Pain

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN(C)CCCN1c2ccccc2CCc2ccccc21

                

                

                
                

                    
InChI

                    
InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H24N2

                    

                    
                    

                        
HBD / HBA

                        
- / 2

                    

                    
                    

                        
Вращаемые Связи

                        
4

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
21

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
This tricyclic antidepressant (TCA) works by blocking the reuptake of serotonin and norepinephrine, increasing the availability of these neurotransmitters in the brain. It is used to treat depression, anxiety disorders, and childhood enuresis (bedwetting). Like all TCAs, it has more side effects than newer antidepressants and can be dangerous in overdose.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Imipramine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL11.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3696.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.